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A B S T R A C T
Introduction. Combined hormonal contraceptives (CHCs) use is becoming an increasingly recognized causes of
vestibulodynia.
Aim. This study aims to describe pre- and posttreatment vestibular pain, sex hormone binding globulin (SHBG),
and calculated free testosterone levels in women undergoing treatment for vestibulodynia.
Methods. This was a chart review of 50 premenopausal women who presented with vestibular pain while currently
using CHCs. Pre- and posttreatment vestibular pain, SHBG, and calculated free testosterone levels were assessed.
Results. There was a statistically signiﬁcant improvement in posttreatment vestibular pain scores (P = 0.001), SHBG
(P = 0.001), and calculated free testosterone (P = 0.001) levels from baseline.
Conclusion. Women with vestibulodynia that began while on CHC may effectively be treated by discontinuing the
CHC combined with the application topical hormone therapy. Symptomatic improvement is accompanied by
normalization of calculated free testosterone and SHBG values. Burrows LJ and Goldstein AT. The treatment of
vestibulodynia with topical estradiol and testosterone. Sex Med 2013;1:30–33.
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Introduction
Vestibulodynia, also known as provoked local-ized vulvodynia and formerly termed the
“vulvar vestibulitis syndrome,” is characterized by
a severe, burning/sharp pain that occurs in
response to pressure localized to the vulvar vesti-
bule. Vestibulodynia is a common cause of
dyspareunia with an estimated prevalence of 15%
among women presenting for general gynecologic
care [1]. Painful intercourse (dyspareunia) as well
as pain with tampon insertion are hallmarks of this
condition. Although there are likely multiple
causes of vestibular pain, the relationship to com-
bined hormonal contraceptive (CHC) use is
becoming increasingly recognized.
Several studies have demonstrated thatCHCuse
signiﬁcantly increases the risk of developing
vestibulodynia [2–5]. There are several contribut-
ing factors that may explain this observation.
Due to the fact that CHCs inhibit luteinizing
hormone, there is a decreased ovarian production
of testosterone. In addition, both the synthetic
estrogen and synthetic progestin component of
CHCs, which are metabolized in the liver, leads to
increased hepatic production of sex hormone
binding globulin (SHBG). The combination of
lower total testosterone production from the
ovaries combined with the increased levels of
SHBG in turn lead to decreased levels of
circulating free testosterone. It has been suggested
that CHC with newer progestins lower free
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testosterone greater than CHC with the earlier
progestins [6].
The vulvar vestibule is embryologically analo-
gous to the male urethra. The mucin-secreting,
androgen-dependant Cowper’s glands and glands
of Litre in men are the embryologic analogs to the
Bartholin glands and minor vestibular glands in
women. It has been shown that these vestibular
glands are rich in androgen receptors [7]. In addi-
tion to alterations in serum hormone and SHBG
levels, CHCs have been shown to induce changes
in hormone receptors as well as alter the morpho-
logical pattern in the vestibular mucosa [8]. In
addition, CHC have been shown to lower the pain
threshold of the vulvar vestibule [9].
Interestingly, the vestibule is not the only
female genital structure to sustain detrimental
effects from CHCs. A recent study assessed the
affects of 30 mg ethinyl estradiol and 3 mg
drospirenone (YasminTM, Bayer, Leverkusen,
Germany) on the thickness of the labia minora and
vaginal introitus area. After only 3 months of use,
the subjects experienced worsening of pain with
intercourse, decreased thickness of the labia
minora, decreased diameter of the vaginal
introitus, and decreased size of the glans clitoris in
comparison with the baseline values [10]. Bohm-
Starke et al. report that some women with
vestibulodynia had resolution of symptoms after
discontinuing CHC (personal communication).
In 2008, The National Survey of Family
Growth found that 82% of American women age
18–44 had used the oral contraceptive pill at some
point in their life, and among women under age
30, a higher percentage of women used the pill
than any other method of contraception. Although
CHCs are highly reliable in the prevention of
pregnancy, like any other medication, they have
potential side effects. Clinicians must be aware
that (ironically) vestibular pain and dyspareunia
are potential side effects of CHCs.
The authors have previously hypothesized that
CHC that changes to the vestibular mucosa
induced by CHCs are a potential cause of
vestibulodynia [11]. Herein, we describe our treat-
ment approach to and clinical outcomes in pre-
menopausal women with vestibulodynia who
presented to a vulvar pain clinic while currently
taking CHCs.
Methods
After obtaining approval from the Anne Arundel
Medical Center Institutional Review Board, the
database for The Center for Vulvovaginal Disor-
ders was utilized to identify 50 consecutive pre-
menopausal women with vestibulodynia who were
using CHCs at the time they presented for care. All
women had previously had pain-free intercourse
and had subsequently developed vestibular pain
(i.e., secondary vestibulodynia). As is our standard
practice, all patients were asked to discontinue
CHCs, and patients were asked to apply a com-
pounded preparation of topical estradiol 0.03%
and testosterone 0.01% to the vestibule twice daily.
Testosterone was used in treatment as a recent
study examining the impact of vaginal testosterone
alone on vaginal atrophy demonstrated improve-
ment in vaginal atrophy symptoms [12].
Patients who had other causes of vestibular pain
such as pelvic ﬂoor muscle hypertonus, infection,
and vulvar dermatoses were excluded from this
review; thus, only patients inwhomCHCswere the
only identiﬁable cause of their vestibular pain were
included. Data abstracted included age, average
time takingCHCs, baseline and posttreatment ves-
tibular pain scores, SHBG, and calculated free tes-
tosterone levels aswell as treatment time (inweeks).
Vestibular pain was assessed using a moist cotton
swab. If the vestibular pain in a given patient varied
at different locations on the vestibule, the highest
score was used when calculating the average pre-
and postvestibular pain scores. Descriptive statis-
tics and t-tests were applied as appropriate.
Results
The average age was 26 years, and the average
duration of CHC use was 7 years. The most com-
monly used CHHs were LoEstrin (Duramed,
Tikva, Israel) (n = 6), Yasmin (n = 6), and Yaz
(Bayer) (n = 5). Vestibular pain scores decreased
from 7.5 to 2 (P = 0.001, see Figures 1 and 2).
Baseline and posttreatment SHBG levels were
154 nmol/L and 64 nmol/L, respectively (P =
0.001), and calculated free testosterone levels were
0.193 ng/dL and 0.813 ng/dL, respectively (P =
0.001, see Figures 3 and 4). The average duration
of treatment was 20 weeks.
Discussion
The potential for negative side effects from CHCs
on female sexuality in general is a subject of
debate. Perhaps the most widely studied aspect of
female sexuality as it relates to CHC use is libido.
To date, studies have yielded conﬂicting results
with some studies showing improvement, others a
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decrease in, and others showing no effect on
female desire with CHC use [13]. Interestingly,
the proposed explanation of decreased libido in
CHC users is the same as what we are hypothesiz-
ing causes vestibular pain: elevated SHBG and
decrease calculated free testosterone levels.
Although several studies have shown that
CHCs increase a woman’s risk of developing
vestibulodynia, other studies have not demon-
strated this effect [14,15]. Unfortunately, these
studies did not control for the type of CHC used or
length of use. Although some studies have assessed
hormone receptor expression in the vulvar vesti-
bule and found no difference between women with
vestibulodynia and pain-free controls, CHC use
was not controlled for [16]. Nevertheless, thou-
sands of women suffer from vestibular pain and are
seeking relief. Although there are undoubtedly
A B
Figure 1 (A) Before estradiol and
testosterone. (B) After estradiol and
testosterone
Figure 2 Pre- and posttreatment vestibular pain scores
Calcultated free testosterone ng/dL
Figure 3 Pre- and posttreatment calculate free
testosterone
SHBG nmol/L
Figure 4 Pre- and posttreatment sex hormone binding
globulin (SHBG) levels
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many causes of vestibular pain, this study pro-
vides further evidence to support a hormonally
mediated cause, speciﬁcally one induced by CHCs.
This study has demonstrated that women with
vestibulodyniawho have no other identiﬁable cause
of their pain that began while taking CHCs are
effectively treated by discontinuing the CHCs
combined with the application topical hormone
therapy. Furthermore, subjective improvement is
accompanied by normalization of calculated free
testosterone and SHBG values.
Panzer et al. found that in women with sexual
dysfunction, SHBG levels in women who discon-
tinued CHCs did not decrease to values of women
who never used CHCs [17]. Although the present
study noted a marked decrease in SHBG levels, it
is unknown if the patients decreased to their base-
line level. The hypothesis put forth by Panzer
et al. suggesting that prolonged exposure to the
synthetic estrogens in CHCs induced gene
imprinting and increased gene expression of
SHBG in the liver is an interesting one and merits
further investigation.
There are many limitations of this study, includ-
ing those inherent to a retrospective review, the lack
of a standardized questionnaire, lack of a standard-
ized instrument to assess vestibular pain (such as a
vulvalgesiometer), lack of placebo control, and tes-
tosterone levels that were drawn randomly during
themenstrual cycle. In addition, subjects effectively
underwent three concurrent interventions: cessa-
tion of CHC, application of topical estradiol, and
the application of topical testosterone. As such, we
cannot know the relative importance of each of
these three interventions in the patients’ improve-
ment in symptoms. A prospective, randomized,
placebo-controlled trial is needed to ascertain if all
three components of this treatment regimen are
needed to treat women with hormonally mediated
vestibulodynia. Therefore, until these trial are
completed and despite the aforementioned limita-
tions of this study, we suggest that women with
secondary vestibulodynia that developed while on
CHC be considered for the treatment approach
described in this article.
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